Studying the Impact of European Union Regulatory Interventions for Minimising Risks From Medicines: Lessons Learnt and Recommendations
Open Access
- 2 August 2024
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (8) , e5874
Abstract
Purpose: The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) launched a strategy to examine the public health impact of major regulatory interventions aimed at minimising risks of medicinal products. We conducted a lessons learnt analysis of impact studies completed between 2015 and 2023.Methods: We surveyed PRAC Sponsors and (Co‐)Rapporteurs involved in the evaluation of 12 impact studies (10 commissioned by EMA and 2 conducted collaboratively by Member States) to explore how these support regulatory decision‐making. Questions covered achievement of study objectives, risk minimisation effectiveness, added value for regulatory decision‐making, and recommendations for future impact studies. Themes were generated using thematic content analysis.Results: Survey responses from 15 PRAC Sponsors and (Co‐)Rapporteurs from 10 European Union Member States were included in the analysis. Among four cross‐sectional surveys and eight drug utilisation studies, 50% achieved all objectives, the other studies partially due to limitations. Two studies concluded that risk minimisation measures were overall effective, two were effective with variation across countries, two were partially effective and four studies showed limited effectiveness. Two studies were deemed inconclusive due to limitations. The reasons for the limited effectiveness of risk minimisation may be explored using mixed‐method approaches. Assessment of study feasibility and a priori discussion of effectiveness measurements is important.Conclusion: Despite limitations, impact research adds value to regulatory decision‐making by addressing knowledge gaps and providing additional information on unintended consequences of regulatory interventions. Our recommendations will help to improve planning, conducting and interpretating future impact studies.Keywords
This publication has 7 references indexed in Scilit:
- Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018–2021: A Qualitative Analysis of Industry‐Sponsored Post‐Authorization Safety StudiesClinical Pharmacology & Therapeutics, 2024
- Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021Clinical Pharmacology & Therapeutics, 2023
- The Use of Real‐World Data to Assess the Impact of Safety‐Related Regulatory InterventionsClinical Pharmacology & Therapeutics, 2021
- Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risksExpert Opinion on Drug Safety, 2021
- Measuring the impact of medicines regulatory interventions – Systematic review and methodological considerationsBritish Journal of Clinical Pharmacology, 2017
- Methodological gaps in the assessment of risk minimization interventions: a systematic reviewPharmacoepidemiology and Drug Safety, 2014
- A critical review of methods to evaluate the impact of FDA regulatory actionsPharmacoepidemiology and Drug Safety, 2013